HALO logo

Halozyme Therapeutics (HALO) EBITDA

Annual EBITDA

$656.54 M
+$204.59 M+45.27%

December 31, 2024

Summary

Performance

1-Year Change

+45.27%

3-Year Change

+153.45%

5-Year Change

+1260.87%

15-Year Change

+665.6%

HALO EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

93.37%
HALO annual EBITDA is higher than 93.37% of companies in Healthcare sector

High & Low

All-time High

$656.54 M
HALO annual EBITDA is currently at an all-time high

3-Year Low

$259.04 M
HALO annual EBITDA is currently +153.45% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2024
HALO previous annual earnings announcement was published on Dec 31, 2024

Next Annual Earnings Report Date

N/A
HALO next annual earnings announcement has not yet been scheduled

OtherHALOprofitabilitymetrics:

Annual Revenue

$1.02 B
HALO annual revenue is $1.02 billion

Annual Net Income

$444.09 M
HALO annual net profit is $444.09 million

Annual EBIT

$575.23 M
HALO annual earnings before interest & taxes is $575.23 million

Annual EPS

$3.43
HALO annual earnings per share is $3.43

Quarterly EBITDA

$203.17 M
+$13.14 M+6.91%

December 31, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

+59.86%

3-Year Change

+57.08%

5-Year Change

+57.08%

HALO Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

93.42%
HALO quarterly EBITDA is higher than 93.42% of companies in Healthcare sector

High & Low

All-time High

$203.17 M
HALO quarterly EBITDA is currently at an all-time high

3-Year Low

$45.66 M
HALO quarterly EBITDA is currently +344.95% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
HALO previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 7, 2025
HALO next earnings announcement is scheduled for May 7, 2025

OtherHALOprofitabilitymetrics:

Quarterly Revenue

$298.01 M
HALO quarterly revenue is $298.01 million

Quarterly Net Income

$137.01 M
HALO quarterly net profit is $137.01 million

Quarterly EBIT

$182.75 M
HALO quarterly earnings before interest & taxes is $182.75 million

Quarterly EPS

$1.06
HALO quarterly earnings per share is $1.06

TTM EBITDA

$656.54 M
+$76.08 M+13.11%

December 31, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

+45.27%

3-Year Change

+61.18%

5-Year Change

+61.18%

HALO TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

93.09%
HALO TTM EBITDA is higher than 93.09% of companies in Healthcare sector

High & Low

All-time High

$656.54 M
HALO TTM EBITDA is currently at an all-time high

3-Year Low

$256.86 M
HALO TTM EBITDA is currently +155.61% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
HALO previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 7, 2025
HALO next earnings announcement is scheduled for May 7, 2025

OtherHALOprofitabilitymetrics:

TTM Revenue

$1.02 B
HALO TTM revenue is $1.02 billion

TTM Net Income

$444.09 M
HALO TTM net profit is $444.09 million

TTM EBIT

$575.23 M
HALO TTM earnings before interest & taxes is $575.23 million

TTM EPS

$3.43
HALO TTM earnings per share is $3.43

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Annual EBITDA

$656.54 M
HALO annual EBITDA is $656.54 million

Annual Net Income

$444.09 M
HALO annual net profit is $444.09 million

Annual Interest Expense

$18.09 M
HALO annual interest expense is $18.09 million

Annual Income Tax

$113.04 M
HALO annual income tax is $113.04 million

Annual D&A

$81.31 M
HALO annual depreciation & amortization is $81.31 million

HALO EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+45.3%+59.9%+45.3%
3 y3 years+153.4%+57.1%+61.2%
5 y5 years+1260.9%+57.1%+61.2%

HALO EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+153.4%at high+344.9%at high+155.6%
5 y5-yearat high+1260.9%at high+784.4%at high+1151.2%
alltimeall timeat high+926.1%at high+784.4%at high+795.3%

Halozyme Therapeutics EBITDA History

DateAnnualQuarterlyTTM
Dec 2024
$656.54 M(+45.3%)
$203.17 M(+6.9%)
$656.54 M(+13.1%)
Sep 2024
-
$190.03 M(+33.3%)
$580.46 M(+11.7%)
Jun 2024
-
$142.60 M(+18.1%)
$519.77 M(+4.9%)
Mar 2024
-
$120.74 M(-5.0%)
$495.45 M(+9.6%)
Dec 2023
$451.95 M(+43.2%)
$127.09 M(-1.7%)
$451.95 M(+11.0%)
Sep 2023
-
$129.34 M(+9.4%)
$407.33 M(+4.9%)
Jun 2023
-
$118.28 M(+53.1%)
$388.42 M(+23.0%)
Mar 2023
-
$77.24 M(-6.3%)
$315.80 M(+0.1%)
Dec 2022
$315.51 M(+21.8%)
$82.47 M(-25.3%)
$315.51 M(+8.5%)
Sep 2022
-
$110.42 M(+141.8%)
$290.67 M(+13.2%)
Jun 2022
-
$45.66 M(-40.7%)
$256.86 M(-15.8%)
Mar 2022
-
$76.95 M(+33.5%)
$305.20 M(+17.8%)
Dec 2021
$259.04 M(+69.3%)
$57.64 M(-24.8%)
$259.04 M(-7.6%)
Sep 2021
-
$76.61 M(-18.5%)
$280.49 M(+14.0%)
Jun 2021
-
$94.00 M(+205.3%)
$245.94 M(+33.9%)
Mar 2021
-
$30.79 M(-61.1%)
$183.64 M(+20.1%)
Dec 2020
$152.96 M(-370.5%)
$79.08 M(+88.0%)
$152.96 M(+246.1%)
Sep 2020
-
$42.06 M(+32.7%)
$44.19 M(-323.3%)
Jun 2020
-
$31.70 M(>+9900.0%)
-$19.79 M(-68.3%)
Mar 2020
-
$113.00 K(-100.4%)
-$62.46 M(+10.4%)
Dec 2019
-$56.56 M(-4.7%)
-$29.69 M(+35.4%)
-$56.56 M(+132.4%)
Sep 2019
-
-$21.92 M(+100.0%)
-$24.33 M(-4.1%)
Jun 2019
-
-$10.96 M(-282.3%)
-$25.36 M(-20.4%)
Mar 2019
-
$6.01 M(+137.1%)
-$31.87 M(-46.3%)
Dec 2018
-$59.36 M(-169.2%)
$2.54 M(-111.0%)
-$59.36 M(-190.5%)
Sep 2018
-
-$22.95 M(+31.4%)
$65.60 M(-33.0%)
Jun 2018
-
-$17.47 M(-18.7%)
$97.92 M(+7.7%)
Mar 2018
-
-$21.48 M(-116.8%)
$90.91 M(+6.0%)
Dec 2017
$85.75 M(-207.9%)
$127.50 M(+1261.8%)
$85.75 M(-235.4%)
Sep 2017
-
$9.36 M(-138.3%)
-$63.31 M(-33.0%)
Jun 2017
-
-$24.47 M(-8.1%)
-$94.43 M(+4.2%)
Mar 2017
-
-$26.64 M(+23.5%)
-$90.66 M(+14.1%)
Dec 2016
-$79.47 M(+213.5%)
-$21.57 M(-0.9%)
-$79.47 M(+53.3%)
Sep 2016
-
-$21.75 M(+5.1%)
-$51.83 M(-1.9%)
Jun 2016
-
-$20.70 M(+34.0%)
-$52.83 M(+92.7%)
Mar 2016
-
-$15.45 M(-354.2%)
-$27.42 M(+8.1%)
Dec 2015
-$25.35 M(-58.5%)
$6.08 M(-126.7%)
-$25.35 M(-27.3%)
Sep 2015
-
-$22.76 M(-582.9%)
-$34.87 M(+14.1%)
Jun 2015
-
$4.71 M(-135.2%)
-$30.55 M(-38.5%)
Mar 2015
-
-$13.39 M(+289.4%)
-$49.65 M(-18.7%)
Dec 2014
-$61.03 M(-22.7%)
-$3.44 M(-81.4%)
-$61.03 M(-22.3%)
Sep 2014
-
-$18.44 M(+28.2%)
-$78.52 M(+0.4%)
Jun 2014
-
-$14.38 M(-42.0%)
-$78.22 M(-8.6%)
Mar 2014
-
-$24.77 M(+18.4%)
-$85.61 M(+8.4%)
Dec 2013
-$78.98 M
-$20.93 M(+15.4%)
-$78.98 M(+27.0%)
Sep 2013
-
-$18.14 M(-16.7%)
-$62.17 M(-2.5%)
DateAnnualQuarterlyTTM
Jun 2013
-
-$21.77 M(+20.0%)
-$63.75 M(+14.4%)
Mar 2013
-
-$18.14 M(+340.1%)
-$55.74 M(+6.2%)
Dec 2012
-$52.47 M(+181.0%)
-$4.12 M(-79.1%)
-$52.47 M(-21.1%)
Sep 2012
-
-$19.72 M(+43.4%)
-$66.46 M(+60.7%)
Jun 2012
-
-$13.75 M(-7.6%)
-$41.35 M(+70.7%)
Mar 2012
-
-$14.88 M(-17.8%)
-$24.22 M(+29.7%)
Dec 2011
-$18.67 M(-64.6%)
-$18.11 M(-436.0%)
-$18.67 M(+3.2%)
Sep 2011
-
$5.39 M(+59.4%)
-$18.10 M(-49.1%)
Jun 2011
-
$3.38 M(-136.2%)
-$35.56 M(-29.9%)
Mar 2011
-
-$9.33 M(-46.8%)
-$50.71 M(-3.9%)
Dec 2010
-$52.75 M(-7.5%)
-$17.54 M(+45.3%)
-$52.75 M(+11.1%)
Sep 2010
-
-$12.07 M(+2.6%)
-$47.49 M(-3.1%)
Jun 2010
-
-$11.76 M(+3.4%)
-$48.99 M(-9.2%)
Mar 2010
-
-$11.38 M(-7.4%)
-$53.96 M(-5.4%)
Dec 2009
-$57.01 M(+15.4%)
-$12.28 M(-9.5%)
-$57.01 M(-7.2%)
Sep 2009
-
-$13.57 M(-18.9%)
-$61.47 M(+4.5%)
Jun 2009
-
-$16.73 M(+16.0%)
-$58.82 M(+10.5%)
Mar 2009
-
-$14.43 M(-13.8%)
-$53.21 M(+7.7%)
Dec 2008
-$49.39 M(+79.1%)
-$16.74 M(+53.3%)
-$49.39 M(+16.6%)
Sep 2008
-
-$10.92 M(-1.9%)
-$42.36 M(+7.0%)
Jun 2008
-
-$11.13 M(+4.9%)
-$39.60 M(+15.8%)
Mar 2008
-
-$10.61 M(+9.2%)
-$34.19 M(+24.0%)
Dec 2007
-$27.57 M(+79.8%)
-$9.71 M(+19.1%)
-$27.57 M(+22.8%)
Sep 2007
-
-$8.16 M(+42.9%)
-$22.46 M(+24.3%)
Jun 2007
-
-$5.71 M(+43.0%)
-$18.06 M(+15.0%)
Mar 2007
-
-$3.99 M(-13.1%)
-$15.71 M(+2.4%)
Dec 2006
-$15.34 M(+14.9%)
-$4.60 M(+22.2%)
-$15.34 M(+7.5%)
Sep 2006
-
-$3.76 M(+12.1%)
-$14.27 M(+0.3%)
Jun 2006
-
-$3.36 M(-7.2%)
-$14.23 M(+3.4%)
Mar 2006
-
-$3.62 M(+2.6%)
-$13.75 M(+3.0%)
Dec 2005
-$13.36 M(+49.0%)
-$3.53 M(-5.2%)
-$13.36 M(+8.4%)
Sep 2005
-
-$3.72 M(+29.0%)
-$12.32 M(+4.2%)
Jun 2005
-
-$2.88 M(-10.4%)
-$11.82 M(+7.5%)
Mar 2005
-
-$3.22 M(+29.4%)
-$11.00 M(+22.7%)
Dec 2004
-$8.96 M(<-9900.0%)
-$2.49 M(-23.0%)
-$8.96 M(+64.7%)
Sep 2004
-
-$3.23 M(+56.9%)
-$5.44 M(+109.3%)
Jun 2004
-
-$2.06 M(+73.6%)
-$2.60 M(+190.1%)
Mar 2004
-
-$1.19 M(-214.9%)
-$896.50 K(-1721.2%)
Dec 2003
$0.00(0.0%)
$1.03 M(-366.3%)
$55.30 K(-105.8%)
Sep 2003
-
-$387.70 K(+9.1%)
-$958.70 K(+64.3%)
Jun 2003
-
-$355.20 K(+51.6%)
-$583.60 K(+136.6%)
Mar 2003
-
-$234.30 K(-1366.5%)
-$246.70 K(<-9900.0%)
Dec 2002
$0.00(-100.0%)
$18.50 K(-246.8%)
$0.00(-100.0%)
Sep 2002
-
-$12.60 K(-31.1%)
-$18.50 K(+213.6%)
Jun 2002
-
-$18.30 K(-247.6%)
-$5900.00(-147.6%)
Mar 2002
-
$12.40 K
$12.40 K
Dec 2001
-$39.70 K
-
-

FAQ

  • What is Halozyme Therapeutics annual EBITDA?
  • What is the all time high annual EBITDA for Halozyme Therapeutics?
  • What is Halozyme Therapeutics annual EBITDA year-on-year change?
  • What is Halozyme Therapeutics quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Halozyme Therapeutics?
  • What is Halozyme Therapeutics quarterly EBITDA year-on-year change?
  • What is Halozyme Therapeutics TTM EBITDA?
  • What is the all time high TTM EBITDA for Halozyme Therapeutics?
  • What is Halozyme Therapeutics TTM EBITDA year-on-year change?

What is Halozyme Therapeutics annual EBITDA?

The current annual EBITDA of HALO is $656.54 M

What is the all time high annual EBITDA for Halozyme Therapeutics?

Halozyme Therapeutics all-time high annual EBITDA is $656.54 M

What is Halozyme Therapeutics annual EBITDA year-on-year change?

Over the past year, HALO annual EBITDA has changed by +$204.59 M (+45.27%)

What is Halozyme Therapeutics quarterly EBITDA?

The current quarterly EBITDA of HALO is $203.17 M

What is the all time high quarterly EBITDA for Halozyme Therapeutics?

Halozyme Therapeutics all-time high quarterly EBITDA is $203.17 M

What is Halozyme Therapeutics quarterly EBITDA year-on-year change?

Over the past year, HALO quarterly EBITDA has changed by +$76.08 M (+59.86%)

What is Halozyme Therapeutics TTM EBITDA?

The current TTM EBITDA of HALO is $656.54 M

What is the all time high TTM EBITDA for Halozyme Therapeutics?

Halozyme Therapeutics all-time high TTM EBITDA is $656.54 M

What is Halozyme Therapeutics TTM EBITDA year-on-year change?

Over the past year, HALO TTM EBITDA has changed by +$204.59 M (+45.27%)